WNT2 and colorectal cancer: found a negative correlation between WNT2+ CAFs and active CD8+ T cells in primary ESCC, and anti-WNT2 monoclonal antibody (mAb) could restore anti-tumor immune responses and enhance the efficacy of anti-PD-1 in both mouse ESCC and colorectal cancer syngeneic tumor models (51).